GentleFectTM is a non-viral, non-liposomal peptide-based delivery platform designed forthe efficient transfection of primary cells and a broad spectrum of nucleic acid cargos, including plasmid DNA, mRNA, siRNA, and circRNA. By integrating a benign peptide architecture with controlled self-assembly, the system achieves high transfection efficiency while preserving cellular viability, providing a critical balance for gene-editing workflows and cell-therapy manufacturing. Engineered for GMP-compatible processes, GentleFectTM delivers a scalable and reproducible solution that meets the stringent demands of industrial-scale bioproduction.
REFERENCE
[ 1 ]. Sun, Y, Wu, X, Li, J. et al. Phase-separating peptide coacervates with programmable material properties for universal intracellular delivery of macromolecules. Nat Commun 15, 10094 (2024).
[ 2 ]. Sun, Y, Lau, S.Y, Lim, Z.W. et al. Phase-separating peptides for direct cytosolic delivery and redox-activated release of macromolecular therapeutics. Nat. Chem. 14,274-283 (2022).